Opinion|Videos|December 17, 2024
Key Insights on the Use of Inhaled Treprostinil in Treating CTD-PAH
Author(s)Steven D. Nathan, MD
Key Takeaways
- Development of therapies that halt or reverse IPF and PAH progression is a significant unmet need.
- Improved diagnostic tools are essential for earlier detection and intervention in IPF and PAH.
Steven Nathan, MD, discusses how the study on inhaled treprostinil for CTD-PAH demonstrates its comparable efficacy to intravenous and subcutaneous forms, with a better safety profile, which could lead to improved patient adherence and management of CTD-PAH.
Advertisement
Episodes in this series
- Briefly describe the abstract “Inhaled Treprostinil for the Treatment of Connective Tissue-Associated Pulmonary Arterial Hypertension.”
- What was the objective of this study?
- How was this study designed/what methodology was used?
- What results were presented?
- What are your key takeaways from this study, and what are the clinical implications in utilizing inhaled treprostinil compared with intravenous or subcutaneous treprostinil for connective tissue disease-associated PAH?
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Three Years on Baricitinib Preserved Hair Regrowth in Severe Alopecia Areata
2
Oz White House Briefing Touts Drug Savings and Fraud Cleanup, but Data Tell a Nuanced Story
3
First Clinical Evidence of Gene Editing, Epigenetic Silencing of HBV cccDNA
4
5 Notable Oncology FDA Approvals Granted in May
5